Trevena, Inc. to Present First-in-Man Study Results for Mu-Opioid Biased Ligand TRV130
3/18/2013 9:59:47 AM
KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced today that Michael Lark, Ph.D., Chief Scientific Officer, will present the results of a Phase 1 first-in-man study on the safety, tolerability, and pharmacology of TRV130 in healthy volunteers, as a poster at the American Academy of Neurology meeting, to be held in San Diego on March 16th through 23rd, 2013. The poster will be presented on Tuesday, March 19th. In this study, which was completed in 2012, TRV130 was safe and generally well-tolerated, and showed pharmacodynamic effects that were consistent with its exciting preclinical profile. TRV130’s pharmacokinetic profile was also shown to be suitable for an intermittent-use intravenous drug. Trevena is developing TRV130 for the intravenous treatment of acute moderate-to-severe post-operative pain. The data supports TRV130 progression to its next clinical study, in which analgesic efficacy and tolerability will be compared directly with intravenous morphine, a gold-standard post-operative analgesic.